florfenicol / terbinafine hydrochloride / mometasone furoate
Table of contents
Neptra is a veterinary medicine used to treat dogs with short lived or recurrent ear infections (otitis externa) caused by two organisms: Staphylococcus pseudintermedius (a bacterium) and Malassezia pachydermatitis (a yeast). Neptra contains three active substances: florfenicol, terbinafine and mometasone.
Neptra : EPAR - Medicine overview (PDF/119.06 KB)
First published: 09/01/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Bayer Animal Health GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
16/07/2021 Neptra - EMEA/V/C/004735 - IB/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Corticosteroids and antiinfectives in combination
For the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis).
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 8-10 December 202011/12/2020